Anti-Hu CD170 Purified SIGLEC5 Monoclonal Antibody

CD170, also known as Siglec 5 (sialic acid binding Ig-like lectin 5) is a type 1 transmembrane glycoprotein containing two cytoplasmic immunoreceptor tyrosine inhibitory motifs (ITIMs) . CD170 forms homodimers and functions as an inhibitory receptor able to downregulate cell activation. It binds to alpha2,3- and alpha2,6-linked sialic acid ligands, e.g. on glycophorin A (CD235a) . Aberrant expression of CD170 by CD34+ progenitor cells can be observed in case of acute myeloid leukemias.

As in case with other anti-CD170 antibodies, this antibody cross-reacts with Siglec-14, whose first two Ig domains are almost identical to those of CD170.

Fusion protein composed of human CD170 extracellular domain and Fc region of human IgG1. The mouse monoclonal antibody 1A5 recognizes an extracellular epitope of CD170 (Siglec-5, sialic acid binding Ig-like lectin 5), a transmembrane glycoprotein expressed strongly by neutrophils, macrophages activated during infections, monocytes, and dendritic cells.

Expressed by monocytic/myeloid lineage cells. Found at high levels in peripheral blood leukocytes, spleen, bone marrow and at lower levels in lymph node, lung, appendix, placenta, pancreas and thymus. Expressed by monocytes and neutrophils but absent from leukemic cell lines representing early stages of myelomonocytic differentiation.

Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds equally to alpha-2,3-linked and alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.